Directory Category: Drug Discovery
Ubiquigent Obtains Exclusive License for UbiSite Technology to Strengthen its Specialist Drug Discovery Services
Dundee, UK, 31 October 2022: Ubiquigent Limited (Ubiquigent), a
drug discovery and development company harnessing novel deubiquitylase
(DUB) modulators as new therapeutics for areas of high unmet medical
need, has signed an exclusive license with the University of Southern
Denmark for its UbiSite technology. UbiSite will form a new component
in Ubiquigentís DUB and ubiquitin-proteasome system (UPS) focused drug
discovery platform, providing a fully supported ubiquitomics service to
facilitate target identification, target validation, and compound
mechanism of action.
Ubiquigent Appoints Dr Sheelagh Frame, CSO, to Its Board of Directors
Dundee, UK, 24 October 2022: Ubiquigent Limited (Ubiquigent), a
drug discovery and development company harnessing novel deubiquitylase
(DUB) modulators as powerful new therapeutics, today announced the
appointment of Dr Sheelagh Frame, Chief Scientific Officer (CSO), to the
Companyís Board of Directors. The appointment comes at a key stage in
the Companyís development with the growing importance of the DUBs in
drug discovery and will help drive the progress of Ubiquigentís internal
portfolio of novel DUB modulators, associated drug discovery programmes
and commercial services.
Vetter Drives its Sustainability Campaign Forward
Repeat participation in Baden Wuerttembergís Sustainability Days
Greater inclusion of employees due to involvement in various initiatives
Awards pay tribute to a comprehensive sustainability strategy
